

## ADRA1D Antibody (N-term)

Purified Rabbit Polyclonal Antibody (Pab)

Catalog # AW5131

### Product Information

---

<b>Application</b>	IHC-P, FC, WB
<b>Primary Accession</b>	<a href="#">P25100</a>
<b>Reactivity</b>	Mouse, Rat, Human
<b>Predicted</b>	Rabbit, Dog, Sheep, Bovine
<b>Host</b>	Rabbit
<b>Clonality</b>	Polyclonal
<b>Calculated MW</b>	60463
<b>Isotype</b>	Rabbit IgG
<b>Antigen Source</b>	HUMAN

### Additional Information

---

<b>Gene ID</b>	146
<b>Antigen Region</b>	1-30
<b>Other Names</b>	Alpha-1D adrenergic receptor, Alpha-1A adrenergic receptor, Alpha-1D adrenoreceptor, Alpha-1D adrenoceptor, Alpha-adrenergic receptor 1a, ADRA1D, ADRA1A
<b>Dilution</b>	IHC-P~~1:100~500 FC~~1:25 WB~~1:1000
<b>Target/Specificity</b>	This ADRA1D antibody is generated from a rabbit immunized with a KLH conjugated synthetic peptide between 1-30 amino acids from the N-terminal region of human ADRA1D.
<b>Format</b>	Purified polyclonal antibody supplied in PBS with 0.09% (W/V) sodium azide. This antibody is purified through a protein A column, followed by peptide affinity purification.
<b>Storage</b>	Maintain refrigerated at 2-8°C for up to 2 weeks. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.
<b>Precautions</b>	ADRA1D Antibody (N-term) is for research use only and not for use in diagnostic or therapeutic procedures.

### Protein Information

---

<b>Name</b>	ADRA1D ( <a href="#">HGNC:280</a> )
<b>Synonyms</b>	ADRA1A

## Function

Alpha-1 adrenergic receptors are G protein-coupled receptors for catecholamines that signal through the G(q) family of G proteins, including G(q) and G(11). Upon activation, they stimulate the phosphatidylinositol-calcium second messenger pathway, leading to calcium release from intracellular stores and activation of protein kinase C (PubMed:[7746284](#)). ADRA1D binds the catecholamine ligands norepinephrine and epinephrine (PubMed:[7815325](#), PubMed:[8024574](#), PubMed:[8183249](#)).

## Cellular Location

Cell membrane; Multi-pass membrane protein.


## Background

This alpha-adrenergic receptor mediates its effect through the influx of extracellular calcium.


## References

Bruno J.F.,et al.Biochem. Biophys. Res. Commun. 179:1485-1490(1991).  
Forray C.,et al.Mol. Pharmacol. 45:703-708(1994).  
Schwinn D.A.,et al.J. Pharmacol. Exp. Ther. 272:134-142(1995).  
Weinberg D.H.,et al.Biochem. Biophys. Res. Commun. 201:1296-1304(1994).  
Esbenshade T.A.,et al.Mol. Pharmacol. 47:977-985(1995).

## Images




Western blot analysis of lysates from A549 cell line, rat brain tissue, LNCaP, PC-3 cell line (from left to right), using ADRA1D Antibody (N-term)(Cat. #AW5131). AW5131 was diluted at 1:1000 at each lane. A goat anti-rabbit IgG H&L(HRP) at 1:10000 dilution was used as the secondary antibody.




Flow cytometric analysis of MCF-7 cells using ADRA1D Antibody (N-term)(green, Cat#AW5131) compared to an isotype control of rabbit IgG(blue). AW5131 was diluted at 1:25 dilution. An Alexa Fluor® 488 goat anti-rabbit IgG at 1:400 dilution was used as the secondary antibody.


Immunohistochemical analysis of paraffin-embedded H. kidney section using ADRA1D Antibody (N-term)(Cat#AW5131). AW5131 was diluted at 1:100 dilution. A peroxidase-conjugated goat anti-rabbit IgG at 1:400 dilution was used as the secondary antibody, followed by DAB staining.



Immunohistochemical analysis of paraffin-embedded H. small intestine section using ADRA1D Antibody (N-term)(Cat#AW5131). AW5131 was diluted at 1:100 dilution. A peroxidase-conjugated goat anti-rabbit IgG at 1:400 dilution was used as the secondary antibody, followed by DAB staining.



Immunohistochemical analysis of paraffin-embedded R. kidney section using ADRA1D Antibody (N-term)(Cat#AW5131). AW5131 was diluted at 1:100 dilution. A peroxidase-conjugated goat anti-rabbit IgG at 1:400 dilution was used as the secondary antibody, followed by DAB staining.



Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.